• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Cyclic AMP-dependent transcription factor ATF-7 (ATF7)

ACP03642

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP03642 Target NameATF7
FormLiquid or Lyophilized powderExpression SystemE.coli
Expression Range1-117aaMol Weight40.3kDa
Protein LengthFull Length of BC042363PurityGreater than 90% as determined by SDS-PAGE.
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDP17544
Background Information
  • Uniprot Id

    P17544

  • Target Species

    Human

  • Target Name

    ATF7

  • Target Full Name

    Cyclic AMP-dependent transcription factor ATF-7

  • Target Function

    Stress-responsive chromatin regulator that plays a role in various biological processes including innate immunological memory, adipocyte differentiation or telomerase regulation. In absence of stress, contributes to the formation of heterochromatin and heterochromatin-like structure by recruiting histone H3K9 tri- and di-methyltransferases thus silencing the transcription of target genes such as STAT1 in adipocytes, or genes involved in innate immunity in macrophages and adipocytes. Stress induces ATF7 phosphorylation that disrupts interactions with histone methyltransferase and enhances the association with coactivators containing histone acetyltransferase and/or histone demethylase, leading to disruption of the heterochromatin-like structure and subsequently transcriptional activation. In response to TNF-alpha, which is induced by various stresses, phosphorylated ATF7 and telomerase are released from telomeres leading to telomere shortening. Plays also a role in maintaining epithelial regenerative capacity and protecting against cell death during intestinal epithelial damage and repair.; Acts as a dominant repressor of the E-selectin/NF-ELAM1/delta-A promoter.; Acts as a negative regulator, inhibiting both ATF2 and ATF7 transcriptional activities. It may exert these effects by sequestrating in the cytoplasm the Thr-53 phosphorylating kinase, preventing activation.

  • Target Subcellular Location

    Nucleus. Nucleus, nucleoplasm. Chromosome, telomere. Note=Mainly nucleoplasmic. Restricted distribution to the perinuculear region. The sumoylated form locates to the nuclear periphery.; [Isoform 5]: Cytoplasm.

  • Target Protein Families

    BZIP family

  • Target Tissue Specificity

    Expressed in various tissues including heart, brain, placenta, lung and skeletal muscle. Highest levels in skeletal muscle. Lowest in lung and placenta.; [Isoform 4]: Strongly expressed in skeletal muscle. Also expressed at lower levels in heart and lung.

  • Target Research Area

    Epigenetics and Nuclear Signaling

  • Target Synonyms

    1110012F10Rik; 9430065F09Rik; Activating transcription factor 7; AI549878; ATF7; Atf7 protein; ATF7_HUMAN; ATFA; C130020M04Rik; cAMP-dependent transcription factor ATF-7; Cyclic AMP-dependent transcription factor ATF 7; Cyclic AMP-dependent transcription factor ATF-7; MGC31554; MGC57182; Transcription factor ATF A; Transcription factor ATF-A

  • Target Background

    Enables several functions, including DNA-binding transcription repressor activity, RNA polymerase II-specific; mitogen-activated protein kinase binding activity; and transcription coactivator binding activity. Involved in negative regulation of transcription by RNA polymerase II and positive regulation of transcription by RNA polymerase II. Located in nucleoplasm. Biomarker of colorectal cancer.

Inquire Recombinant Human Cyclic AMP-dependent transcription factor ATF-7 (ATF7) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification